Monia Brett P sold $6.8M of IONS
Monia Brett P (Chief Executive Officer) sold 85,637 shares of IONIS PHARMACEUTICALS INC (IONS) at an average of $79.70 ($78.41–$80.59, $6.83M total) across 3 trades over 2026-06-24 to 2026-06-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed open-market sale totaling $6.83M across three trades at $78.41–$80.59, with remaining holdings of 245,571 shares after the sale.
Market read
Insider selling can create short-term sentiment noise, but the 10b5-1 structure makes it less actionable for fundamental repricing.
What to watch
Traders may over-weight insider sales; without accompanying guidance, trial, or regulatory updates, the signal is mostly sentiment rather than fundamentals.
Background
This is an SEC Form 4 insider transaction disclosure for Ionis Pharmaceuticals (IONS) by CEO Monia Brett P.
Ticker impact
Ionis Pharmaceuticals CEO Monia Brett P sold $6.83M of IONS shares via an open-market transaction under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.
Form 4 shows a planned 10b5-1 sale with disclosed pricing range and post-transaction holdings, which typically reduces interpretive signal versus discretionary selling.
Market effects
Minimal; insider-sale disclosures rarely reset sector expectations for biotech unless tied to other material events.
None indicated; US-listed biotech filing only.
None indicated; no cross-border deal/regulatory action described.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.
Key entities
- public_companyIonis Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction; CEO Monia Brett P sold shares totaling $6.83M under a 10b5-1 plan.
- insiderMonia Brett P
CEO and officer/director who executed the open-market sale disclosed in the Form 4.
